Efficacia del beclometasone nella profilassi del wheezing virale

Studio ENBe

Translated title of the contribution: Efficacy of nebulised beclometasone in viral wheezing prophylaxis

Antonio Clavenna, Marco Sequi, Massimo Cartabia, Filomena Fortinguerra, Marta Borghi, Maurizio Bonati

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives To evaluate the efficacy of nebulised beclometasone in preventing the recurrence of viral wheezing. Patients and methods The ENBe study was designed in two phase: a randomized double blind placebo-controlled trial (phase I) followed by an observational follow-up period (phase II). Only phase I will be described in this paper. Outpatient children 1-5 years old with upper respiratory tract infection and at least one episode of viral wheezing in the last 12 months were randomly allocated to receive nebulised beclometasone 400 μg or placebo twice daily for 10 days. A clinical evaluation was performed by the pediatrician at the start and end of the treatment period. A subjective evaluation of symptoms and efficacy of treatment was performed by the parents. The primary endpoint was the incidence of viral wheezing diagnosed by the pediatricians during the 10 day treatment period. Results A total of 525 children were enrolled in the study and 521 of which were visited at the end of the treatment period. Wheezing was diagnosed by pediatricians in 47 children (9.0%) with no statistically significant differences between treatment groups (beclometasone vs placebo relative risk=0.61, 95%CI 0.35-1.08). No differences were found regarding the asthma-like symptom score, while 63% of parents rated the treatment as helpful (64% in beclometasone versus 61% in placebo group). In all, 46% of children had still infection symptoms at the end of the treatment period, without differences between groups. Conclusions The findings from this study confirm that inhaled steroids are not effective in preventing viral wheezing recurrence. Moreover, no benefits were found in reducing symptoms of respiratory tract infections.

Original languageItalian
Pages (from-to)194-201
Number of pages8
JournalQuaderni ACP
Volume20
Issue number5
Publication statusPublished - 2013

Fingerprint

Beclomethasone
Respiratory Sounds
Placebos
Respiratory Tract Infections
Therapeutics
Parents
Recurrence
Symptom Assessment
Outpatients
Asthma
Steroids
Incidence
Infection
Pediatricians

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Clavenna, A., Sequi, M., Cartabia, M., Fortinguerra, F., Borghi, M., & Bonati, M. (2013). Efficacia del beclometasone nella profilassi del wheezing virale: Studio ENBe. Quaderni ACP, 20(5), 194-201.

Efficacia del beclometasone nella profilassi del wheezing virale : Studio ENBe. / Clavenna, Antonio; Sequi, Marco; Cartabia, Massimo; Fortinguerra, Filomena; Borghi, Marta; Bonati, Maurizio.

In: Quaderni ACP, Vol. 20, No. 5, 2013, p. 194-201.

Research output: Contribution to journalArticle

Clavenna, A, Sequi, M, Cartabia, M, Fortinguerra, F, Borghi, M & Bonati, M 2013, 'Efficacia del beclometasone nella profilassi del wheezing virale: Studio ENBe', Quaderni ACP, vol. 20, no. 5, pp. 194-201.
Clavenna, Antonio ; Sequi, Marco ; Cartabia, Massimo ; Fortinguerra, Filomena ; Borghi, Marta ; Bonati, Maurizio. / Efficacia del beclometasone nella profilassi del wheezing virale : Studio ENBe. In: Quaderni ACP. 2013 ; Vol. 20, No. 5. pp. 194-201.
@article{3fffe5c89b3b46f5a3af19beb6aa7c02,
title = "Efficacia del beclometasone nella profilassi del wheezing virale: Studio ENBe",
abstract = "Objectives To evaluate the efficacy of nebulised beclometasone in preventing the recurrence of viral wheezing. Patients and methods The ENBe study was designed in two phase: a randomized double blind placebo-controlled trial (phase I) followed by an observational follow-up period (phase II). Only phase I will be described in this paper. Outpatient children 1-5 years old with upper respiratory tract infection and at least one episode of viral wheezing in the last 12 months were randomly allocated to receive nebulised beclometasone 400 μg or placebo twice daily for 10 days. A clinical evaluation was performed by the pediatrician at the start and end of the treatment period. A subjective evaluation of symptoms and efficacy of treatment was performed by the parents. The primary endpoint was the incidence of viral wheezing diagnosed by the pediatricians during the 10 day treatment period. Results A total of 525 children were enrolled in the study and 521 of which were visited at the end of the treatment period. Wheezing was diagnosed by pediatricians in 47 children (9.0{\%}) with no statistically significant differences between treatment groups (beclometasone vs placebo relative risk=0.61, 95{\%}CI 0.35-1.08). No differences were found regarding the asthma-like symptom score, while 63{\%} of parents rated the treatment as helpful (64{\%} in beclometasone versus 61{\%} in placebo group). In all, 46{\%} of children had still infection symptoms at the end of the treatment period, without differences between groups. Conclusions The findings from this study confirm that inhaled steroids are not effective in preventing viral wheezing recurrence. Moreover, no benefits were found in reducing symptoms of respiratory tract infections.",
keywords = "Beclometasone, Child preschool, Physicians, Primary care, Randomized controlled trial",
author = "Antonio Clavenna and Marco Sequi and Massimo Cartabia and Filomena Fortinguerra and Marta Borghi and Maurizio Bonati",
year = "2013",
language = "Italian",
volume = "20",
pages = "194--201",
journal = "Quaderni ACP",
issn = "2039-1374",
publisher = "Associazione Cultur Pediatri",
number = "5",

}

TY - JOUR

T1 - Efficacia del beclometasone nella profilassi del wheezing virale

T2 - Studio ENBe

AU - Clavenna, Antonio

AU - Sequi, Marco

AU - Cartabia, Massimo

AU - Fortinguerra, Filomena

AU - Borghi, Marta

AU - Bonati, Maurizio

PY - 2013

Y1 - 2013

N2 - Objectives To evaluate the efficacy of nebulised beclometasone in preventing the recurrence of viral wheezing. Patients and methods The ENBe study was designed in two phase: a randomized double blind placebo-controlled trial (phase I) followed by an observational follow-up period (phase II). Only phase I will be described in this paper. Outpatient children 1-5 years old with upper respiratory tract infection and at least one episode of viral wheezing in the last 12 months were randomly allocated to receive nebulised beclometasone 400 μg or placebo twice daily for 10 days. A clinical evaluation was performed by the pediatrician at the start and end of the treatment period. A subjective evaluation of symptoms and efficacy of treatment was performed by the parents. The primary endpoint was the incidence of viral wheezing diagnosed by the pediatricians during the 10 day treatment period. Results A total of 525 children were enrolled in the study and 521 of which were visited at the end of the treatment period. Wheezing was diagnosed by pediatricians in 47 children (9.0%) with no statistically significant differences between treatment groups (beclometasone vs placebo relative risk=0.61, 95%CI 0.35-1.08). No differences were found regarding the asthma-like symptom score, while 63% of parents rated the treatment as helpful (64% in beclometasone versus 61% in placebo group). In all, 46% of children had still infection symptoms at the end of the treatment period, without differences between groups. Conclusions The findings from this study confirm that inhaled steroids are not effective in preventing viral wheezing recurrence. Moreover, no benefits were found in reducing symptoms of respiratory tract infections.

AB - Objectives To evaluate the efficacy of nebulised beclometasone in preventing the recurrence of viral wheezing. Patients and methods The ENBe study was designed in two phase: a randomized double blind placebo-controlled trial (phase I) followed by an observational follow-up period (phase II). Only phase I will be described in this paper. Outpatient children 1-5 years old with upper respiratory tract infection and at least one episode of viral wheezing in the last 12 months were randomly allocated to receive nebulised beclometasone 400 μg or placebo twice daily for 10 days. A clinical evaluation was performed by the pediatrician at the start and end of the treatment period. A subjective evaluation of symptoms and efficacy of treatment was performed by the parents. The primary endpoint was the incidence of viral wheezing diagnosed by the pediatricians during the 10 day treatment period. Results A total of 525 children were enrolled in the study and 521 of which were visited at the end of the treatment period. Wheezing was diagnosed by pediatricians in 47 children (9.0%) with no statistically significant differences between treatment groups (beclometasone vs placebo relative risk=0.61, 95%CI 0.35-1.08). No differences were found regarding the asthma-like symptom score, while 63% of parents rated the treatment as helpful (64% in beclometasone versus 61% in placebo group). In all, 46% of children had still infection symptoms at the end of the treatment period, without differences between groups. Conclusions The findings from this study confirm that inhaled steroids are not effective in preventing viral wheezing recurrence. Moreover, no benefits were found in reducing symptoms of respiratory tract infections.

KW - Beclometasone

KW - Child preschool

KW - Physicians

KW - Primary care

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=84897586049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897586049&partnerID=8YFLogxK

M3 - Articolo

VL - 20

SP - 194

EP - 201

JO - Quaderni ACP

JF - Quaderni ACP

SN - 2039-1374

IS - 5

ER -